Biogen, Schering-Plough regulatory update

The FDA approved Intron A (Interferon alfa-2b) for injection as an adjuvant to surgery in patients at high risk for systemic recurrence of malignant melanoma. In trials, the addition of Intron A after surgical removal of the tumor increased median survival overall by more than 12 months (45.8 vs. 33.4 months) and median relapse-free survival by nine months (20.6 vs. 11.8 months). The product was developed by BGEN and is sold by Schering-Plough. ...